Abba Medix Group Inc. Announces Warrant Extension
TORONTO, ONTARIO -- (Marketwired) -- 01/26/16 -- Abba Medix Group Inc. (the "Company" or "Abba") (CSE: ABA) is pleased to announce that it has received approval from the Canadian Securities Exchange to extend the expiry term of 5,487,723 common share purchase warrants (the "Warrants") issued as a part of its 2015 reverse take-over transaction. This amendment represents the first amendment made to the Warrants.
The original expiry date of the Warrants was March 13, 2016. The new expiry date of the Warrants is March 13, 2018. All other terms and conditions of the Warrants remain unchanged. The Company will deliver a notice reflecting the amended expiry date to the registered holders of the Warrants.
About Abba Medix Group Inc.
Abba Medix Group Inc. (CSE: ABA) is the parent company of Abba Medix Corp.; a company committed to becoming a purveyor of fine medical cannabis in Canada. In compliance with Health Canada's regulations, the Company's goal is to become a marketplace leader through strategic partnerships, mergers, and acquisitions to create a fully integrated medical cannabis marketplace. Abba's mission is to find, acquire or create joint venture opportunities in patient focused medical cannabis related companies, products, organizational events, sponsorships, educational training, and research and development within medical cannabis sector. For more information please visit www.abbamedix.com.
Contacts: Ray Ahmad Rasouli Chief Executive Officer Abba Medix Group Inc. Tel: (905) 492-9420
Source: Abba Medix Group Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Exclusive: National Vision CEO on traffic, ticket growth and the digital shift
- FDA Advisory Committee Votes In Favor of Approval of GRAIL's Galleri® Multi-Cancer Early Detection Test
- Hemostemix files Form 4B for third tranche of private placement
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share